Effects of contrast media on renal function in patients with cirrhosis: A prospective study

Hepatology

Volumn 40, Issue 3, 2004, Pages 646-651

  Guevara, Mònica ^a,b,c   Fernández Esparrach, Glòria ^a,b   Alessandria, Carlo ^a,b,c   Torre, Aldo ^a,b,c   Terra, Carlos ^a,b,c   Montañà, Xavier ^a   Piera, Carlos ^a   Alvarez, Maria Luisa ^a   Jiménez, Wladimiro ^a,b   Ginès, Pere ^a,b,c   Arroyo, Vicente ^a,b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c Inst Reina Sofia Invest N   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; IODINE 125; IODOHIPPURATE SODIUM I 123; PROSTAGLANDIN; SODIUM; ACETYLGLUCOSAMINIDASE;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; FEMALE; FREE WATER CLEARANCE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; KIDNEY TUBULE DAMAGE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTAGLANDIN URINE LEVEL; RADIODIAGNOSIS; RISK FACTOR; SEPTIC SHOCK; SODIUM URINE LEVEL; AGED; DRUG EFFECT; KIDNEY; KIDNEY CIRCULATION; MIDDLE AGED; URINE;

ACETYLGLUCOSAMINIDASE; ADULT; AGED; CONTRAST MEDIA; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL CIRCULATION;

EID: 4544362451     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20373     Document Type: Article

References (32)

1. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003;362:1819-1827.
2. Gines P, Rodes J. Clinical disorders of renal function in cirrhosis with ascites. In: Arroyo V, Gines P, Rodes J, eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis and Treatment. Malden, MA: Blackwell Science, 1999:36-62.
3. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. HEPATOLOGY 2003;37:233-243.
4. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. HEPATOLOGY 1996;23:164-176.
5. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors, and prognosis. HEPATOLOGY 1994;20:1495-1501.
6. Cardenas A, Gines P, Uriz J, Bessa X, Salmeron JM, Mas A, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. HEPATOLOGY 2001;34(pt 1):671-676.
7. Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493-1502.
8. Cabrera J, Arroyo V, Ballesta AM, Rimola A, Gual J, Elena M, et al. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982;82:97-105.
9. Salerno F, Badalamenti S. Frug-induced renal failure in cirrhosis. In: Arroyo V, Gines P, Rodes J, Schrier RW, eds. Ascites and renal dysfunction in liver disease. Malden, MA: Blackwell Science, Inc., 1998:511-521.
10. Morcos SK. Contrast media-induced nephrotoxicity - questions and answers. Br J Radiol 1998;71:357-365.
11. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 1999;9:1602-1613.
12. Waybill MM, Waybill PN. Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interv Radiol 2001;12:3-9.
13. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995;47:254-261.
14. Barrett BJ, Parfrey PS. Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 1994;331:1449-1450.
15. Uriz J, Gines P, Ortega R, Jimenez W, Cardenas A, Calahorra B, et al. Increased plasma levels of neuropeptide Y in hepatorenal syndrome. J Hepatol 2002;36:349-355.
16. Planas R, Arroyo V, Rimola A, Perez-Ayuso RM, Rodes J. Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983;84:247-252.
17. Quintero E, Ginès P, Arroyo V, Rimola A, Camps J, Gaya J, et al. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites. Nephron 1986;42:298-303.
18. Llach J, Ginès P, Arroyo V, Salmeron JM, Gines A, Jimenez W, et al. Effect of dipyridamole on kidney function in cirrhosis. HEPATOLOGY 1993;17:59-64.
19. Laffi G, Daskalopoulos G, Kronborg I, Hsueh W, Gentilini P, Zipser RD. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Gastroenterology 1986;90:182-187.
20. Banares R, Moitinho E, Matilla A, Garcia-Pagan JC, Lampreave JL, Piera C, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. HEPATOLOGY 2002;36:1367-1373.
21. Daskalopoulos G, Pinzani M, Murray N, Hirschberg R, Zipser RD. Effects of captopril on renal function in patients with cirrhosis and ascites. J Hepatol 1987;4:330-336.
22. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. HEPATOLOGY 2002;36(pt 1):941-948.
23. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-930.
24. Porter GA. Urinary biomarkers and nephrotoxicity. Miner Electrolyte Metab 1994;20:181-186.
25. Hofmeister R, Bhargava AS, Gunzel P. Value of enzyme determinations in urine for the diagnosis of nephrotoxicity in rats. Clin Chim Acta 1986;160:163-167.
26. Jung K. Urinary enzymes and low molecular weight proteins as markers of tubular dysfunction. Kidney Int Suppl 1994;47:S29-S33.
27. Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994;94:1069-1075.
28. Brezis M, Cronin RE. Radiocontrast media-induced acute renal failure. In: Schrier RW, ed. Disease of the Kidney and Urinary Tract. Philadelphia: Lippincott Williams & Wilkins, 2001:1121-1254.
29. Arroyo V, Gines P, Rimola A, Gaya J. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med 1986;81:104-122.
30. Epstein M, Lifschitz M, Ramachandran M, Rappaport K. Characterization of renal prostaglandin E responsiveness in decompensated cirrhosis: implications for renal sodium handling. Clin Sci (Lond) 1982;63:555-563.
31. Guarner C, Colina I, Guarner F, Corzo J, Prieto J, Vilardell F. Renal prostaglandins in cirrhosis of the liver. Clin Sci (Lond) 1986;70:477-484.
32. Price RG. Measurement of N-acetyl-beta-glucosaminidase and its isoenzymes in urine methods and clinical applications. Eur J Clin Chem Clin Biochem 1992;30:693-705.